CR20230261A - Cocristal de un inhibidor de cdk - Google Patents

Cocristal de un inhibidor de cdk

Info

Publication number
CR20230261A
CR20230261A CR20230261A CR20230261A CR20230261A CR 20230261 A CR20230261 A CR 20230261A CR 20230261 A CR20230261 A CR 20230261A CR 20230261 A CR20230261 A CR 20230261A CR 20230261 A CR20230261 A CR 20230261A
Authority
CR
Costa Rica
Prior art keywords
cocrystal
cdk inhibitor
relates
cdk7
fumarate
Prior art date
Application number
CR20230261A
Other languages
English (en)
Inventor
Sangamesh Eshwarappa Badiger
Uday Bhat
Ranadeep Bokalial
Krishnnaswamy Devanathan
Original Assignee
Aurigene Oncology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Oncology Ltd filed Critical Aurigene Oncology Ltd
Publication of CR20230261A publication Critical patent/CR20230261A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/15Fumaric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere al compuesto de fumarato de fórmula (I) y su forma cristalina y métodos para su preparación. La invención también se relaciona con preparaciones adecuadas para usos farmacéuticos para el tratamiento de diversas enfermedades o trastornos mediados por CDK7, particularmente cáncer u otras enfermedades proliferativas
CR20230261A 2020-12-18 2021-12-17 Cocristal de un inhibidor de cdk CR20230261A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202041055174 2020-12-18
PCT/IB2021/061895 WO2022130304A1 (en) 2020-12-18 2021-12-17 Cocrystal of a cdk inhibitor

Publications (1)

Publication Number Publication Date
CR20230261A true CR20230261A (es) 2023-10-04

Family

ID=80001496

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230261A CR20230261A (es) 2020-12-18 2021-12-17 Cocristal de un inhibidor de cdk

Country Status (17)

Country Link
US (1) US20240059669A1 (es)
EP (1) EP4263534A1 (es)
JP (1) JP2023554492A (es)
KR (1) KR20230159363A (es)
CN (1) CN116685326A (es)
AU (1) AU2021402415A1 (es)
CA (1) CA3202198A1 (es)
CL (1) CL2023001753A1 (es)
CO (1) CO2023009368A2 (es)
CR (1) CR20230261A (es)
DO (1) DOP2023000126A (es)
EC (1) ECSP23054131A (es)
IL (1) IL303738A (es)
MX (1) MX2023007218A (es)
PE (1) PE20231441A1 (es)
TW (1) TW202241881A (es)
WO (1) WO2022130304A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023224961A1 (en) 2022-05-16 2023-11-23 Exelixis, Inc. Cancer therapy using a combination of a cdk7 inhibitor with an oral serd

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016193939A1 (en) 2015-06-04 2016-12-08 Aurigene Discovery Technologies Limited Substituted heterocyclyl derivatives as cdk inhibitors

Also Published As

Publication number Publication date
IL303738A (en) 2023-08-01
WO2022130304A1 (en) 2022-06-23
CO2023009368A2 (es) 2023-09-29
KR20230159363A (ko) 2023-11-21
CA3202198A1 (en) 2022-06-23
JP2023554492A (ja) 2023-12-27
DOP2023000126A (es) 2023-11-30
CN116685326A (zh) 2023-09-01
EP4263534A1 (en) 2023-10-25
US20240059669A1 (en) 2024-02-22
AU2021402415A1 (en) 2023-07-06
PE20231441A1 (es) 2023-09-14
CL2023001753A1 (es) 2024-02-02
TW202241881A (zh) 2022-11-01
ECSP23054131A (es) 2023-09-29
MX2023007218A (es) 2023-07-27

Similar Documents

Publication Publication Date Title
CR20220363A (es) Compuestos tricíclicos sustituidos
CR20220312A (es) Compuestos tricíclicos sustituidos
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
WO2018198077A3 (en) 6-6 FUSIONED BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS INHIBITORS OF LATS
DE602004015810D1 (de) Substituierte isochinolinderivate und anwendungsverfahren
CA2962914C (en) Compounds and compositions for modulating egfr mutant kinase activities
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
EP4327877A3 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2022015531A (es) Derivado de piridina-pirimidina, metodo de preparacion y uso farmaceutico del mismo.
MX2021003945A (es) Compuestos de indolinona para uso como inhibidores de map4k1.
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
MX2023003627A (es) Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer.
EP4342473A3 (en) Compounds useful in hiv therapy
MX2022000083A (es) Inhibidores de monoacilglicerol lipasa (magl) heterociclicos.
MX2022006333A (es) Compuesto triheterociclico como inhibidor de jak y uso del mismo.
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
AU2019375825A8 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
MX2022010795A (es) Hidrato cristalino de un compuesto inhibidor de jak.
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
MX2023007218A (es) Cocristal de un inhibidor de cinasa dependiente de ciclina (cdk).
MX2022008627A (es) Pirazolo-pirimidinas sustituidas y usos de las mismas.
JOP20210319A1 (ar) مركبات بيروليدين
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy